

Shilpa Paul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/449299/publications.pdf>

Version: 2024-02-01

44
papers

583
citations

759233

12
h-index

642732

23
g-index

44
all docs

44
docs citations

44
times ranked

934
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	11
2	Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management. <i>Current Oncology Reports</i> , 2022, 24, 427-436.	4.0	18
3	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	1.4	57
4	Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 658-672.	0.9	4
5	The clinical development of antibody-drug conjugates lessons from leukaemia. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 418-433.	27.6	28
6	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	4.1	24
7	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 61-68.	2.5	2
8	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. <i>Haematologica</i> , 2021, 106, 0-0.	3.5	6
9	Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. <i>Blood</i> , 2021, 138, 631-631.	1.4	1
10	Long-term follow-up of lower dose dasatinib (50Åmg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 67-75.	4.1	87
11	The face of remission induction. <i>British Journal of Haematology</i> , 2020, 188, 101-115.	2.5	3
12	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e10-e13.	2.5	2
13	CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. <i>Cancers</i> , 2020, 12, 3087.	3.7	24
14	Optimizing patient selection for treatment-free remission. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1220-1224.	0.9	0
15	Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. <i>Blood</i> , 2020, 136, 36-37.	1.4	2
16	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2020, 136, 9-11.	1.4	13
17	Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
18	Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories. <i>Blood</i> , 2020, 136, 8-9.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2020, 136, 26-29.	1.4	0
20	655â€¦Concordance between healthcare providers and expert consensus recommendations in the management, monitoring, and mitigation of adverse events associated with CAR T-cell therapy: an updated analysis. , 2020, , .		0
21	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blna): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	1.4	0
22	The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 3-5.	1.4	0
23	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	1.4	0
24	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blna) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	1.4	0
25	Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
26	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 23-25.	1.4	1
27	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 471-479.	0.4	2
28	Blinatumomab for the treatment of acute lymphoblastic leukemia: an update. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 41-46.	0.8	0
29	Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. <i>Future Oncology</i> , 2019, 15, 3885-3894.	2.4	2
30	A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. <i>British Journal of Haematology</i> , 2019, 185, 606-608.	2.5	8
31	Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 719-723.	0.9	1
32	Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3810-3810.	1.4	9
33	Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations. <i>Blood</i> , 2019, 134, 2199-2199.	1.4	0
34	Hepatitis C: When high drug prices preclude patient benefit. <i>Cancer</i> , 2018, 124, 1644-1646.	4.1	1
35	Early results of lower dose dasatinib (50â€‰mg daily) as frontline therapy for newly diagnosed chronicâ€‰phase chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 2740-2747.	4.1	61
36	L-carnitine and Vitamin B Complex for the Treatment of Pegasparginase-induced Hyperbilirubinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e191-e195.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. <i>Blood</i> , 2018, 132, 4367-4367.	1.4	2
38	Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. <i>Blood</i> , 2018, 132, 2702-2702.	1.4	13
39	Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. <i>Blood</i> , 2018, 132, 1417-1417.	1.4	0
40	Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. <i>Future Oncology</i> , 2017, 13, 2233-2242.	2.4	15
41	Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency. <i>Current Drug Safety</i> , 2017, 12, 13-18.	0.6	13
42	Adult Acute Lymphoblastic Leukemia. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1645-1666.	3.0	158
43	Characterizing Melphalan Efficacy and Toxicity in Multiple Myeloma Patients with Renal Insufficiency. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S116.	2.0	0
44	Utilization of antineoplastic chemotherapy near the end of life in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9524-9524.	1.6	0